Pirfenidone for blood vessel scarring in Takayasu arteritis
Treatments studied
Part of Heart & circulation, Skin clinical trials.
This trial tests whether adding pirfenidone (a drug that reduces scarring) to your usual treatment helps limit blood vessel thickening and scarring in Takayasu arteritis. You must still have some signs of active disease despite being on standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with Takayasu arteritis based on standard criteria.
- You are on a stable treatment of steroids and methotrexate (and possibly a biologic) for at least 3 months.
- You still have signs of active disease, such as new or worsening vessel narrowing or ischemic symptoms (e.g., limb pain, dizziness, stroke).
- You do not have other autoimmune diseases (like lupus or rheumatoid arthritis).
- You are not currently taking antifibrotic drugs like nintedanib or pirfenidone.
- You have not had a bad reaction to pirfenidone in the past.
- You are not planning vascular surgery during the next 6 months.
- You are not allergic to MRI contrast agents.
- You can avoid certain medications (like some antibiotics, acid reflux drugs, and others) that interact with pirfenidone.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a personalized treatment plan based on your specific disease markers to standard care, aiming to find which is more effective and safer for active Takayasu's arteritis. It may help researchers learn how to better control inflammation and prevent flares.
This trial tests a drug called secukinumab to see if it can help people with severe Takayasu arteritis, a rare disease that causes inflammation in the blood vessels. The drug works by blocking a protein that drives inflammation, which may reduce disease activity and help people lower their steroid dose.
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
This study looks at whether it is safe for people with Takayasu arteritis to stop taking their biologic medication (like TNF inhibitors or tocilizumab) if they have been in remission—meaning their disease has been quiet—for a long time. You might join this trial if your condition has been stable for years and you haven't needed steroids lately.
This trial tests two drugs, dapagliflozin and bosentan, to see if they help people with large vessel vasculitis who have been in remission for at least 6 months. The goal is to prevent flares and improve blood vessel health.
Hear when a new Takayasu Arteritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.